AITOPAI热报
ProductsSelected73°

Google DeepMind releases AlphaGenome Atlas covering 9 billion DNA variants

Google DeepMind’s AlphaGenome Atlas could help researchers find the genetic causes of diseases

Inquirer: Technology@Julius Tabios
Blog/Media
Read the original
Why we picked it

Precomputed predictions for every possible single-nucleotide change remove the compute barrier that previously limited who could run large-scale variant interpretation, letting wet-lab geneticists work without GPU infrastructure. Research groups studying rare disease, cancer genomics, or population genetics can query it directly to prioritise experiments. It also gives genomics teams outside the US a free resource comparable to internal pipelines at large pharma companies.

Google DeepMind launched AlphaGenome Atlas, a database containing predictions for the molecular effects of roughly 9 billion possible single-letter changes in human DNA.

Body

Researchers can search it to see how individual variants are predicted to affect gene expression, RNA splicing, and chromatin accessibility across different cell types and tissues.

The database builds on DeepMind's earlier AlphaGenome model and aims to speed up the search for genetic causes of diseases.

It makes variant-interpretation predictions available without requiring researchers to run the model themselves.

Original · Inquirer: Technology

Google DeepMind’s AlphaGenome Atlas could help researchers find the genetic causes of diseases

AlphaGenome Atlas contains predictions for the molecular effects of all roughly 9 billion possible single-letter changes in human DNA. Researchers can search the database to see how individual variants are predicted to affect processes such as gene expression, RNA splicing, and chromatin accessibility across different cell types and tissues. That gives researchers something they have

Industry Coordinates & Source Verification

This report is categorized under AITOP's "Products" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows and US-China foundation model benchmarks and commercialization comparison. Key entities and technical topics under continuous tracking include AlphaGenome, Google DeepMind, genomics, multimodal.

Source attribution: curated from Inquirer: Technology (@Julius Tabios).

#AlphaGenome#Google DeepMind#genomics#multimodal

Keep reading

Recent stories with the same tag or section
ModelsBuildersSelected01:30
Google DeepMind Releases AlphaGenome 2 for Cell-Specific Mutation Prediction

The shift from tissue-level blending to single-cell-type prediction makes regulatory variant interpretation more actionable, since most disease-linked non-coding mutations are cell-context dependent. Labs doing genomics, rare disease research or target discovery can apply it to cell types with minimal lab data rather than large training sets. Teams comparing with tools like Enformer or DeepMind's earlier AlphaGenome should note the claimed ~2x gain in detecting gene-expression-regulating mutations as the headline differentiator.

#AlphaGenome#Google DeepMind#genomics#AI for science
The Rundown AI@therundownaiSource
ModelsBuildersSelected00:27
AlphaGenome 2 Launches via API for Non-Commercial Research

API-only access means labs can integrate regulatory predictions into pipelines without GPU infrastructure or model hosting, which shifts the cost of entry from engineering to analysis. Computational biologists, university groups, and biotech research teams working on gene regulation can start experimenting immediately under non-commercial terms. Anyone planning applied or commercial genomics work should check DeepMind's licensing terms first, as the restriction currently blocks revenue-generating use.

#AlphaGenome#Google DeepMind#genomics#API
Sundar Pichai@sundarpichaiSource
ProductsBuildersSelected23:27
Google DeepMind releases AlphaGenome 2 for cell-specific disease research

Cell-specific variant interpretation is a bottleneck in translating genome sequencing into clinical insight, and AlphaGenome 2 targets exactly that gap. Genomics labs, computational biologists, and biotech teams evaluating disease-causing mutations can use it to prioritise variants by affected tissue. Compared with AlphaFold, which resolved protein structure, this model moves DeepMind's tooling upstream into gene regulation, a space where competitors like Enformer and Evotec partnerships have been active.

#AlphaGenome#Google DeepMind#genomics#variant interpretation
Official accountGoogle DeepMind@GoogleDeepMindSource
ModelsBuildersSelected23:27
AlphaGenome 2 predicts cell-specific DNA reading patterns

The interesting shift is that the model's value comes from context — the same variant can be scored across many cell types, enabling tissue-aware interpretation of disease-linked variants that single-context tools miss. Computational biologists, genetics labs and variant-interpretation teams can start experimenting immediately through the free Colab tutorials without infrastructure setup. Commercial users are excluded from the current licence, so biotech teams should treat it as a research preview and watch how DeepMind prices commercial access later.

#AlphaGenome#Google DeepMind#genomics#multimodal
Official accountGoogle DeepMind@GoogleDeepMindSource